Hemab chairman John Maraganore (Ryan Emberley/Getty Images for Klick Inc.)

Rare blood dis­or­ders biotech Hemab rais­es $135M, be­gins trek in­to clin­ic

Hemab Ther­a­peu­tics, led by Al­ny­lam vet Ben­ny Sorensen and chaired by John Maraganore, has raised $135 mil­lion from a new crop of in­vestors as it be­gins push­ing its blood dis­or­der pro­grams in­to the clin­ic.

The raise gives Hemab a cash run­way in­to 2025, and the biotech has a slate of goals it wants to check off be­fore then, in­clud­ing hav­ing five clin­i­cal can­di­dates by 2025. Maraganore said in an in­ter­view with End­points News that the biotech wants to be in Phase III tri­als by then as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.